Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 10/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785638 | 0.89 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3785643 | 0.89 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3785641 | 0.89 | MAPK1 (0.46) | MAPK1RENKMOMAOAMAOB | |
| SCHEMBL3779683 | 0.88 | ITGA4 (0.43) | MAPK1RENITGA4ITGB7KMO | |
| SCHEMBL12053933 | 0.88 | MAPK1 (0.40) | MAPK1RENITGA4ITGB7KMO | |
| SCHEMBL12053935 | 0.86 | MAPK1 (0.38) | MAPK1RENITGA4ITGB7KMO | |
| SCHEMBL12053964 | 0.85 | MAPK1 (0.38) | MAPK1REN | |
| SCHEMBL12053981 | 0.85 | MAPK1 (0.38) | MAPK1RENITGA4ITGB7 | |
| SCHEMBL8229690 | 0.85 | MAPK1 (0.38) | MAPK1RENITGA4ITGB7 | |
| SCHEMBL8229457 | 0.85 | REN (0.40) | MAPK1RENITGA4ITGB7KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2007120523-A2 | 6-(AMINOALKYL)INDAZOLES | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | MAPK1 762/4885REN 1/4885ITGA4 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.